相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ovarian cancer treatment: The end of empiricism?
Stephanie Lheureux et al.
CANCER (2015)
Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research
Kevin M. Elias et al.
GYNECOLOGIC ONCOLOGY (2015)
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives
Koji Matsumoto et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
N. Mohell et al.
CELL DEATH & DISEASE (2015)
Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers
Brandon-Luke L. Seagle et al.
ONCOTARGET (2015)
Predicting survival in head and neck squamous cell carcinoma from TP53 mutation
David L. Masica et al.
HUMAN GENETICS (2015)
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
David D. Bowtell et al.
NATURE REVIEWS CANCER (2015)
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Jaime Prat
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2014)
The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
Pavla Brachova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Role of Glutathione in Cancer Progression and Chemoresistance
Nicola Traverso et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2013)
APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
X. Peng et al.
CELL DEATH & DISEASE (2013)
Evaluating cell lines as tumour models by comparison of genomic profiles
Silvia Domcke et al.
NATURE COMMUNICATIONS (2013)
PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation
Noriko Kobayashi et al.
JOURNAL OF OVARIAN RESEARCH (2013)
P53 and its molecular basis to chemoresistance in breast cancer
Stian Knappskog et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Soren Lehmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cisplatin Treatment of Primary and Metastatic Epithelial Ovarian Carcinomas Generates Residual Cells With Mesenchymal Stem Cell-Like Profile
Ardian Latifi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2011)
Ovarian Cancer Development and Metastasis
Ernst Langyel
AMERICAN JOURNAL OF PATHOLOGY (2010)
Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?
Christopher G. Przybycin et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Yves Pommier et al.
CHEMISTRY & BIOLOGY (2010)
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ashour Ahmed Ahmed et al.
JOURNAL OF PATHOLOGY (2010)
Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis
J. M. R. Lambert et al.
ONCOGENE (2010)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
The fluorometric microculture cytotoxicity assay
Elin Lindhagen et al.
NATURE PROTOCOLS (2008)
PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2
J. Shen et al.
ONCOGENE (2008)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
Molecular mechanisms of resistance and toxicity associated with platinating agents
Cara A. Rabik et al.
CANCER TREATMENT REVIEWS (2007)
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
VJN Bykov et al.
ONCOGENE (2005)
Grading ovarian serous carcinoma using a two-tier system
A Malpica et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Cisplatin: mode of cytotoxic action and molecular basis of resistance
ZH Siddik
ONCOGENE (2003)
Multicellular resistance: a paradigm for clinical resistance?
B Desoize et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2000)
分享论文
